**Chamberlain University – NR 567 / NR-567
Advanced Pharmacology Final Exam Prep (2026 /
2027)**
Master the **NR 567 Advanced Pharmacology Final Exam** with this comprehensive,
highly structured preparation document. Tailored specifically for Chamberlain
University FNP / AGNP graduate nursing students, this guide covers core
pharmacological concepts, drug classifications, mechanisms of action, side effects,
and clinical management scenarios.
### What is Included:
* **Complete Exam Coverage:** High-yield practice questions and detailed concepts
aligned with the official Chamberlain course syllabus.
* **Verified Answers & Rationales:** Clear explanations for correct options to
reinforce clinical decision-making and rationale understanding.
* **Key Topics Covered:**
* Pharmacokinetics & Pharmacodynamics in Advanced Practice
* Cardiovascular, Renal, and Endocrine Pharmacology
* Psychopharmacology & Neurological Agents
* Antimicrobial, Antibacterial, and Antiviral Prescribing Guidelines
* Black Box Warnings, Adverse Effects, and Drug Interactions
* Special Populations (Pediatrics, Geriatrics, Pregnancy/Lactation)
,---
* **Institution:** Chamberlain University
* **Course:** NR 567 / NR-567 (Advanced Pharmacology)
* **Document Type:** Exam Review / Practice Test Bank / Study Guide
* **Format:** PDF / Instant Download
1. Pharmacokinetics, Pharmacodynamics & Organ Dysfunction (Q1–25)
1. A patient with severe septic shock and hypoalbuminemia ($2.1 \text{ g/dL}$)
receives IV Phenytoin for post-traumatic seizures. How does the low albumin level
affect the drug's activity?
o A) Decreases free drug concentration, requiring a higher total dose
o B) Increases the free (active) drug fraction, raising the risk of toxicity at
normal total drug concentrations ✔
o C) Speeds up renal clearance via active transport
o D) Neutralizes hepatic CYP450 metabolism
Rationale: Highly protein-bound drugs (like phenytoin) rely on serum albumin.
In hypoalbuminemia, less drug is bound, increasing the active "free" fraction
and risk of toxicity even if total serum levels appear normal.
2. Which pharmacokinetic parameter best dictates the loading dose required to achieve
an immediate target therapeutic plasma concentration?
, o A) Systemic Clearance ($CL$)
o B) Volume of Distribution ($V_d$) ✔
o C) Elimination Half-life ($t_{1/2}$)
o D) Bioavailability ($F$)
Rationale: Loading dose is calculated as $\text{Loading Dose} = (V_d \times
C_{\text{target}}) / F$. It depends primarily on the volume of distribution,
whereas maintenance dosing depends on clearance.
3. In a patient with end-stage renal disease (ESRD) on hemodialysis, which opioid
active metabolite accumulates rapidly and causes severe respiratory depression and
myoclonus?
o A) Fentanyl
o B) Morphine-6-glucuronide (M6G) and Morphine-3-glucuronide (M3G) ✔
o C) Methadone
o D) Remifentanil
Rationale: Morphine undergoes hepatic glucuronidation to M3G and M6G.
These active metabolites are renally cleared; in renal failure, they
accumulate, leading to neurotoxicity and prolonged respiratory depression.
Fentanyl and Hydromorphone are safer alternatives.
, 4. Hydrophilic antibiotics (e.g., $\beta$-lactams, aminoglycosides, vancomycin) in
critically ill patients with severe edema and aggressive fluid resuscitation require
which initial dosing adjustment?
o A) Increased initial loading dose due to an expanded Volume of
Distribution ($V_d$) ✔
o B) Decreased loading dose due to hepatic congestion
o C) Withholding loading doses until urine output exceeds $1 \text{ mL/kg/hr}$
o D) Transition to oral formulation immediately
Rationale: Sepsis and third-spacing expand extracellular fluid volume,
significantly increasing the $V_d$ of hydrophilic drugs. An increased loading
dose is necessary to establish therapeutic serum levels promptly.
5. Which hepatic enzyme pathway is responsible for Phase I oxidation, reduction, and
hydrolysis reactions that typically decline significantly in elderly patients and severe
cirrhosis?
o A) Glucuronidation (Phase II)
o B) Sulfation (Phase II)
o C) Cytochrome P450 (CYP450) microsomal enzymes (Phase I) ✔
o D) Acetylation (Phase II)
Advanced Pharmacology Final Exam Prep (2026 /
2027)**
Master the **NR 567 Advanced Pharmacology Final Exam** with this comprehensive,
highly structured preparation document. Tailored specifically for Chamberlain
University FNP / AGNP graduate nursing students, this guide covers core
pharmacological concepts, drug classifications, mechanisms of action, side effects,
and clinical management scenarios.
### What is Included:
* **Complete Exam Coverage:** High-yield practice questions and detailed concepts
aligned with the official Chamberlain course syllabus.
* **Verified Answers & Rationales:** Clear explanations for correct options to
reinforce clinical decision-making and rationale understanding.
* **Key Topics Covered:**
* Pharmacokinetics & Pharmacodynamics in Advanced Practice
* Cardiovascular, Renal, and Endocrine Pharmacology
* Psychopharmacology & Neurological Agents
* Antimicrobial, Antibacterial, and Antiviral Prescribing Guidelines
* Black Box Warnings, Adverse Effects, and Drug Interactions
* Special Populations (Pediatrics, Geriatrics, Pregnancy/Lactation)
,---
* **Institution:** Chamberlain University
* **Course:** NR 567 / NR-567 (Advanced Pharmacology)
* **Document Type:** Exam Review / Practice Test Bank / Study Guide
* **Format:** PDF / Instant Download
1. Pharmacokinetics, Pharmacodynamics & Organ Dysfunction (Q1–25)
1. A patient with severe septic shock and hypoalbuminemia ($2.1 \text{ g/dL}$)
receives IV Phenytoin for post-traumatic seizures. How does the low albumin level
affect the drug's activity?
o A) Decreases free drug concentration, requiring a higher total dose
o B) Increases the free (active) drug fraction, raising the risk of toxicity at
normal total drug concentrations ✔
o C) Speeds up renal clearance via active transport
o D) Neutralizes hepatic CYP450 metabolism
Rationale: Highly protein-bound drugs (like phenytoin) rely on serum albumin.
In hypoalbuminemia, less drug is bound, increasing the active "free" fraction
and risk of toxicity even if total serum levels appear normal.
2. Which pharmacokinetic parameter best dictates the loading dose required to achieve
an immediate target therapeutic plasma concentration?
, o A) Systemic Clearance ($CL$)
o B) Volume of Distribution ($V_d$) ✔
o C) Elimination Half-life ($t_{1/2}$)
o D) Bioavailability ($F$)
Rationale: Loading dose is calculated as $\text{Loading Dose} = (V_d \times
C_{\text{target}}) / F$. It depends primarily on the volume of distribution,
whereas maintenance dosing depends on clearance.
3. In a patient with end-stage renal disease (ESRD) on hemodialysis, which opioid
active metabolite accumulates rapidly and causes severe respiratory depression and
myoclonus?
o A) Fentanyl
o B) Morphine-6-glucuronide (M6G) and Morphine-3-glucuronide (M3G) ✔
o C) Methadone
o D) Remifentanil
Rationale: Morphine undergoes hepatic glucuronidation to M3G and M6G.
These active metabolites are renally cleared; in renal failure, they
accumulate, leading to neurotoxicity and prolonged respiratory depression.
Fentanyl and Hydromorphone are safer alternatives.
, 4. Hydrophilic antibiotics (e.g., $\beta$-lactams, aminoglycosides, vancomycin) in
critically ill patients with severe edema and aggressive fluid resuscitation require
which initial dosing adjustment?
o A) Increased initial loading dose due to an expanded Volume of
Distribution ($V_d$) ✔
o B) Decreased loading dose due to hepatic congestion
o C) Withholding loading doses until urine output exceeds $1 \text{ mL/kg/hr}$
o D) Transition to oral formulation immediately
Rationale: Sepsis and third-spacing expand extracellular fluid volume,
significantly increasing the $V_d$ of hydrophilic drugs. An increased loading
dose is necessary to establish therapeutic serum levels promptly.
5. Which hepatic enzyme pathway is responsible for Phase I oxidation, reduction, and
hydrolysis reactions that typically decline significantly in elderly patients and severe
cirrhosis?
o A) Glucuronidation (Phase II)
o B) Sulfation (Phase II)
o C) Cytochrome P450 (CYP450) microsomal enzymes (Phase I) ✔
o D) Acetylation (Phase II)
